DK0787002T3 - Kompetitive progesteronantagonister til behovsorienteret fertilitetskontrol hos kvinder - Google Patents

Kompetitive progesteronantagonister til behovsorienteret fertilitetskontrol hos kvinder

Info

Publication number
DK0787002T3
DK0787002T3 DK95937845T DK95937845T DK0787002T3 DK 0787002 T3 DK0787002 T3 DK 0787002T3 DK 95937845 T DK95937845 T DK 95937845T DK 95937845 T DK95937845 T DK 95937845T DK 0787002 T3 DK0787002 T3 DK 0787002T3
Authority
DK
Denmark
Prior art keywords
oriented
women
needs
progesterone antagonists
competitive progesterone
Prior art date
Application number
DK95937845T
Other languages
Danish (da)
English (en)
Inventor
Kristof Chwalisz
Klaus Stoeckemann
Karin Schmidt-Gollwitzer
Walter Klemann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Application granted granted Critical
Publication of DK0787002T3 publication Critical patent/DK0787002T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK95937845T 1994-10-24 1995-10-24 Kompetitive progesteronantagonister til behovsorienteret fertilitetskontrol hos kvinder DK0787002T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4438820 1994-10-24
PCT/EP1995/004191 WO1996012494A1 (de) 1994-10-24 1995-10-24 Kompetitive progesteronantagonisten zur bedarfsorientierten weiblichen fertilitätskontrolle

Publications (1)

Publication Number Publication Date
DK0787002T3 true DK0787002T3 (da) 2007-04-10

Family

ID=6532105

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95937845T DK0787002T3 (da) 1994-10-24 1995-10-24 Kompetitive progesteronantagonister til behovsorienteret fertilitetskontrol hos kvinder

Country Status (25)

Country Link
US (1) US6143754A (cs)
EP (1) EP0787002B1 (cs)
JP (1) JPH10507461A (cs)
KR (1) KR970706827A (cs)
CN (1) CN1211087C (cs)
AT (1) ATE347894T1 (cs)
AU (1) AU707235B2 (cs)
BG (1) BG62877B1 (cs)
BR (1) BR9509478A (cs)
CA (1) CA2203541A1 (cs)
CZ (1) CZ290690B6 (cs)
DE (1) DE59511071D1 (cs)
DK (1) DK0787002T3 (cs)
ES (1) ES2279515T3 (cs)
FI (1) FI971742L (cs)
HU (1) HU226566B1 (cs)
IL (1) IL115738A (cs)
NO (1) NO314437B1 (cs)
NZ (1) NZ295365A (cs)
PL (1) PL319869A1 (cs)
PT (1) PT787002E (cs)
RO (1) RO120606B1 (cs)
SK (1) SK283662B6 (cs)
WO (1) WO1996012494A1 (cs)
ZA (1) ZA959008B (cs)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19745085A1 (de) * 1997-10-11 1999-04-15 Jenapharm Gmbh 11ß-Benzaldoxim-9alpha,10alpha-epoxy-estr-4-en-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
DE19809845A1 (de) 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
US7629334B1 (en) 1999-08-31 2009-12-08 Bayer Schering Pharma Aktiengesellschaft Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
IL148415A0 (en) * 1999-08-31 2002-09-12 Jenapharm Gmbh Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
PE20010581A1 (es) * 1999-08-31 2001-06-04 Schering Ag Mesoprogestinas (modulares de receptores de progesterona) como componentes de composiciones utilizadas para la terapia de sustitucion hormonal (hrt)
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
WO2009082478A1 (en) * 2007-12-20 2009-07-02 Duramed Pharmaceuticals, Inc. Dosage regimens and pharmaceutical compositions and packages for emergency contraception
CA2757496A1 (en) 2009-04-14 2010-10-21 Andre Ulmann Method for on-demand contraception
CA2758764C (en) * 2009-04-14 2017-04-11 Elizabeth Gray Raymond Method for on-demand contraception using levonorgestrel or norgestrel
BR112015029214A2 (pt) 2013-05-23 2017-07-25 Bayer Pharma AG composição farmacêutica, seu uso e regime de aplicação dessa composição farmacêutica para contracepção conforme a necessidade
CN113559075A (zh) * 2014-11-17 2021-10-29 康泰科思特生物制药公司 奥那司酮延长释放组合物和方法
US10308676B2 (en) 2015-09-25 2019-06-04 Context Biopharma Inc. Methods of making onapristone intermediates
HK1255104A1 (zh) 2015-12-15 2019-08-02 Context Biopharma Inc. 无定形的奥那司酮组合物及其制备方法
WO2018102369A1 (en) 2016-11-30 2018-06-07 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439913A (en) * 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein

Also Published As

Publication number Publication date
MX9703018A (es) 1997-10-31
NO971869L (no) 1997-04-23
FI971742A0 (fi) 1997-04-23
KR970706827A (ko) 1997-12-01
AU3869695A (en) 1996-05-15
DE59511071D1 (de) 2007-01-25
BG101427A (en) 1997-11-28
JPH10507461A (ja) 1998-07-21
EP0787002B1 (de) 2006-12-13
HU226566B1 (en) 2009-04-28
CZ290690B6 (cs) 2002-09-11
CN1211087C (zh) 2005-07-20
US6143754A (en) 2000-11-07
NO314437B1 (no) 2003-03-24
NO971869D0 (no) 1997-04-23
ATE347894T1 (de) 2007-01-15
PT787002E (pt) 2007-03-30
ES2279515T3 (es) 2007-08-16
ZA959008B (en) 1996-09-16
RO120606B1 (ro) 2006-05-30
SK283662B6 (sk) 2003-11-04
FI971742A7 (fi) 1997-04-23
IL115738A (en) 2002-05-23
FI971742L (fi) 1997-04-23
EP0787002A1 (de) 1997-08-06
BR9509478A (pt) 1997-09-30
PL319869A1 (en) 1997-09-01
SK51897A3 (en) 1997-09-10
CN1161649A (zh) 1997-10-08
HUT77518A (hu) 1998-05-28
BG62877B1 (bg) 2000-10-31
CZ118097A3 (en) 1997-07-16
WO1996012494A1 (de) 1996-05-02
AU707235B2 (en) 1999-07-08
NZ295365A (en) 1999-07-29
IL115738A0 (en) 1996-01-19
CA2203541A1 (en) 1996-05-02

Similar Documents

Publication Publication Date Title
DK0787002T3 (da) Kompetitive progesteronantagonister til behovsorienteret fertilitetskontrol hos kvinder
FI963049L (fi) Progesteroniantagonisteja lääkeaineiden valmistamiseksi, jotka on tarkoitettu kohdun toimintahäiriöistä johtuvien verenvuotojen hoitamiseksi
ATE217192T1 (de) Kombinationsprodukt zur kontrazeption enthaltend progesteronantagonisten und gestagenen
EP0402950A3 (en) Treatment of postmenopausal disorders
NO970309L (no) Anvendelse av en progesteronantagonist og av et gestagen for behandling av endometriose eller Leiomyomata uteri
DK0871453T3 (da) Farmaceutisk kombinationspræparat til hormonal kontraception
DE69519933D1 (de) Prostaglandinanaloga zur oralen oder vaginalen verabreichung in der routinebehandlung des dritten stadiums der geburtswehen
PT730448E (pt) Utilizacao de um substrato de sintetase e/ou dador de oxido nitrico ou um inibidor de oxido nitrico para o fabrico de medicamentos para o tratamento de desordens da contractilidade uterina
Szontagh et al. Post-coital contraception with dienoestrol
Board et al. Sequential oral contraception using DMAP
HUP9900313A1 (hu) Antiösztrogének alkalmazása hím nemzőképesség szabályozására
PT1150683E (pt) Utilizacao de dienogest em doses elevadas
Suran Ovulation inhibition with sequential therapy. A continuing clinical study of fertility control
Asbjorn et al. Low dose of gestagen as a contraceptive method. A clinical trial
FR2646354B1 (fr) Utilisation de peptides inhibiteurs de proteases acides pour la preparation de medicaments utiles pour le traitement de maladies virales
JPS56123052A (en) Multiprocessor system
Crist Post-coital estrogen